Manufacturer of Controlled Substances; Notice of Application, 46232 [E9-21524]
Download as PDF
<![CDATA[
46232
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21522 Filed 9–4–09; 8:45 am]
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
Drug
BILLING CODE 4410–09–P
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on June 26,
2009, Noramco Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
made application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to bulk
manufacture the listed controlled
substance as a reference standard for
distribution to its customers which are
analytical laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than November 9, 2009.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21524 Filed 9–4–09; 8:45 am]
DEPARTMENT OF JUSTICE
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by the National
Institute on Drug Abuse.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 9, 2009.
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21526 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Drug Enforcement Administration
Drug
jlentini on DSKJ8SOYB1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 18, 2009,
Research Triangle Institute, Kenneth H.
Davis Jr., Hermann Building, East
Institute Drive, P.O. Box 12194,
Research Triangle, North Carolina
17:32 Sep 04, 2009
Jkt 217001
I
I
II
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 1, 2009,
Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
BILLING CODE 4410–09–P
VerDate Nov<24>2008
Schedule
Schedule
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
4-Methylaminorex (cis isomer)
(1590).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
PO 00000
Frm 00153
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
Drug
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-Phenylcyclohexylamine (7460)
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
Normorphine (9313) .....................
Methamphetamine (1105) ............
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
1Piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Dihydromorphine (9145) ...............
Ecgonine (9180) ...........................
Meperidine intermediate-B (9233)
Noroxymorphone (9668) ..............
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
high purity drug standards used for
analytical application only in clinical,
toxicological, and forensic laboratories.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Page 46232]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21524]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 26, 2009, Noramco Inc.,
Division of Ortho-McNeil, Inc., 500 Swedes Landing Road, Wilmington,
Delaware 19801-4417, made application by letter to the Drug Enforcement
Administration (DEA) for registration as a bulk manufacturer of
Noroxymorphone (9668), a basic class of controlled substance listed in
schedule II.
The company plans to bulk manufacture the listed controlled
substance as a reference standard for distribution to its customers
which are analytical laboratories.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such a substance, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA 22152; and must be filed no later
than November 9, 2009.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-21524 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
